|
Variables
|
Number
|
Surgery (%)
|
Non-surgery (%)
|
χ2
|
P-value
|
|---|
|
Race
| | | | | |
|
White
|
2255
|
968 (42.9%)
|
1287 (57.1%)
|
0.567
|
0.753
|
|
Black
|
462
|
190 (41.1%)
|
272 (58.9%)
| | |
|
Other
|
200
|
87 (43.5%)
|
113 (56.5%)
| | |
|
Ethnic origin
| | | | | |
|
Spanish-Hispanic-Latino
|
289
|
136 (47.1%)
|
153 (52.9%)
|
2.513
|
0.113
|
|
Non-Spanish-Hispanic-Latino
|
2628
|
1109 (42.2%)
|
1519 (57.3%)
| | |
|
Age
| | | | | |
|
≤ 35
|
134
|
67 (50%)
|
67 (50%)
|
21.613
|
< 0.001
|
|
35 < Age < 60
|
1345
|
631 (46%)
|
714 (54%)
| | |
|
≥ 60
|
1438
|
547 (38%)
|
891 (62)
| | |
|
Marital status
| | | | | |
|
Married
|
1416
|
662 (46.8%)
|
754 (53.2%)
|
18.638
|
< 0.001
|
|
Unmarried
|
1501
|
583 (38.8%)
|
918 (61.2%)
| | |
|
Grade
| | | | | |
|
1
|
287
|
99 (34.5%)
|
188 (65.5%)
|
37.276
|
< 0.001
|
|
2
|
1440
|
560 (38.9%)
|
880 (68.1%)
| | |
|
3–4
|
1190
|
586 (49.2%)
|
604 (50.8%)
| | |
|
Laterality
| | | | | |
|
Left
|
1525
|
656 (43%)
|
869 (57%)
|
0.147
|
0.701
|
|
Right
|
1392
|
589 (42.3%)
|
803 (57.7%)
| | |
|
Histology
| | | | | |
|
IDC
|
2351
|
1023 (43.5%)
|
1328 (56.5%)
|
3.433
|
0.064
|
|
Non-IDC
|
566
|
222 (39.2%)
|
344 (60.8%)
| | |
|
T stage
| | | | | |
|
T1
|
383
|
153 (39.9%)
|
230 (60.1%)
|
45.68
|
< 0.001
|
|
T2
|
1158
|
569 (49.1%)
|
589 (50.9%)
| | |
|
T3
|
553
|
242 (43.8%)
|
311 (56.2%)
| | |
|
T4
|
823
|
281 (34.1%)
|
542 (65.9%)
| | |
|
N stage
| | | | | |
|
N0
|
704
|
208 (29.5%)
|
496 (70.5%)
|
258.366
|
< 0.001
|
|
N1
|
1326
|
463 (34.9%)
|
863 (65.1%)
| | |
|
N2
|
406
|
261 (64.3%)
|
145 (35.7)
| | |
|
N3
|
481
|
313 (65.1%)
|
168 (34.9%)
| | |
|
Radiation
| | | | | |
|
Yes
|
1302
|
704 (54.1%)
|
598 (45.9%)
|
124.703
|
< 0.001
|
|
No
|
1615
|
541 (33.5%)
|
1074 (66.5%)
| | |
|
Chemotherapy
| | | | | |
|
Yes
|
1564
|
803 (51.3%)
|
761 (48.7%)
|
103.411
|
< 0.001
|
|
No
|
1353
|
442 (32.7%)
|
911 (67.3%)
| | |
|
Subtype
| | | | | |
|
ER + /HER2−
|
2114
|
869 (41.1%)
|
1245 (58.9%)
|
11.671
|
0.009
|
|
ER + /HER2 +
|
433
|
189 (43.6%)
|
244 (56.4%)
| | |
|
HER2 +
|
122
|
61 (50%)
|
61 (50%)
| | |
|
TNBC
|
248
|
126 (50.8%)
|
122 (49.2%)
| | |
|
ER
| | | | | |
|
Positive
|
2532
|
1050 (41.5%)
|
1482 (58.5%)
|
11.512
|
0.001
|
|
Negative
|
385
|
195 (50.6%)
|
190 (49.4%)
| | |
|
PR
| | | | | |
|
Positive
|
2121
|
886 (41.8%)
|
1235 (58.2%)
|
2.62
|
0.106
|
|
Negative
|
796
|
359 (45.1%)
|
437 (54.9%)
| | |
|
HER2
| | | | | |
|
Positive
|
555
|
250 (45%)
|
305 (55%)
|
1.566
|
0.211
|
|
Negative
|
2362
|
995 (42.1%)
|
1367 (57.9%)
| | |
- ER estrogen receptor, PR progesterone receptor, Her-2 human epidermal growth factor receptor 2, IDC infiltrating ductal carcinoma, TNBC triple-negative breast cancer
